Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?

Impaired Glucose Tolerance Associated With Drugs Clinical Trial

— GREAT  

Official title:

Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? A Randomized, Double-blinded, Placebo-controlled Clinical Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01845259
• Other study ID #: GLP-1 antipsychotics
• Secondary ID: 2013-000121-31U1
• Status: Active, not recruiting
• Phase: Phase 2
• First received: April 14, 2013
• Last updated: May 4, 2016
• Start date: April 2013
• Est. completion date: March 2017

Study information

• Verified date: May 2016
• Source: Psychiatric Centre Rigshospitalet
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Danish Health and Medicines Authority
• Study type: Interventional

Clinical Trial Summary

Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among antipsychotic-treated patients. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic disturbances and can rarely be replaced by other drugs due to the effectiveness of the compounds. Glucagon-like peptide 1 (GLP-1) has improved glycemic control among patients with type 2 diabetes. The study will investigate whether the beneficial effects of GLP-1 analogues on glycemic control in type 2 diabetic patients, can be extended to a population of non-diabetic, dysglycemic psychiatric patients, receiving antipsychotic medical treatment.

Description:

Statistical analyses:

Power calculation:

A sample size of 96 participants (48 in each group) was estimated, with two-sided t-testing, an α of 5% and a power of 90%. The power calculation was based on the primary outcome measurement: Change in glucose tolerance. The glucose tolerance was estimated by the total Area Under the Curve (AUC) following a 4-hour 75-g. Oral Glucose Tolerance Test (OGTT). The expected mean total AUC for the plasma glucose excursion following a 4-hour 75-g. OGTT was estimated as 1695 (SD 158) and 1800 (SD 158) after 16 weeks of treatment for the liraglutide and liraglutide placebo group, respectively. The difference in total AUC was based on unpublished data in individuals with and without Impaired Glucose Tolerance (IGT) following a 4-hour 75-g. OGTT at baseline from the study: "The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes".(1)

Procedure:

All analyses will be carried out with the treatment groups still blinded and labeled as "treatment group A" and "treatment group B". Before dividing participants into group A and group B, the statistical plan was completed and uploaded on clinicaltrials.gov, and the data set was locked. The final unblinding of treatment groups (liraglutide or liraglutide placebo), will not be carried out until all statistical analyses are performed. All analyses will be performed using SAS 9.4, with α set at 0.05 and two-sided testing.

All efficacy analyses will be performed using a modified intention-to-treat principle. All participants who were randomized, received at least one dose of the trial compound (liraglutide or liraglutide placebo) and who had at least one assessment after baseline will be included in the efficacy analyses. All safety analyses will be performed in the intent-to-treat sample that includes all participants, who were randomized and received at least one dose of the trial compound (liraglutide or liraglutide placebo).

Primary endpoint:

The primary endpoint is the change in glucose tolerance following a 4-hour 75-g. OGTT from week 0 to week 16. During the 4-hour 75-g. OGTT, blood was sampled at fixed time points: -15, -10, 0, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180, and 240 minutes. An analysis of covariance (ANCOVA) will be use to analyze change in glucose tolerance from week 0 to week 16 using mixed model analyses for the plasma glucose levels for the liraglutide and the liraglutide placebo group, respectively. In case of relevant baseline differences between the two groups, demographic, illness or treatment parameters will be included in the model as fixed effects together with the baseline value of the OGTTs as a covariate.

Secondary endpoints:

Blood was also sampled for analyses of C-peptide, glucagon and incretin hormones in response to the glucose load at the same fixed time points during the OGTT. Change in secretion of C-peptide, glucagon and incretin hormones from week 0 to week 16 will also be evaluated using mixed model ANCOVA analyses for the liraglutide and liraglutide placebo group, respectively. In case of relevant baseline differences between the two groups, demographic, illness or treatment parameters will be included in the model as fixed effects together with the baseline value of the relevant variable as a covariate.

Most secondary endpoints were repeated every 4 weeks. Few secondary endpoints were only repeated at week 0 and 16. For all repeated measurements a mixed model ANCOVA analyses will be use to analyze mean change in continuous outcomes from week 0 to week 16 for the liraglutide and the liraglutide placebo group, respectively. In case of relevant baseline differences between the two groups, demographic, illness or treatment parameters will be included in the model as fixed effects together with the baseline value of the relevant variable as a covariate. Change in categorical outcomes from week 0 to week 16 will be analyzed using mixed model logistic regression with the same fixed effects and covariates as described for the continuous outcomes.

For secondary endpoints without repeated measurements, missing data imputations will be made using Multiple Imputation of Chained Equations (MICE).

For continuous outcomes without repeated measurements, outcomes will be analyzed using ANCOVA to detect differences between the liraglutide and the liraglutide placebo group. In the model baseline demographic, illness or treatment parameters will be included. Categorical outcomes without repeated measurements will be analyzed using a multiple mixed effect logistic regression analysis model, where baseline demographic, illness or treatment parameters will be included.

Subgroup and sensitivity analyses:

Subgroup and sensitivity analyses will be performed to assess the robustness of the primary analyses. These analyses will be performed using regression analysis for continuous outcomes and logistic regression for categorical outcomes. The analyses will consider clinically or mechanistically relevant baseline and intra-treatment variables, including:

• Gender

• Smoking

• Antipsychotics (clozapine vs olanzapine; monopharmacy vs polypharmacy with other antipsychotic medications)

• Lipid profile

• Liver function

• Different groups of dysglycaemia:

1. HbA1c: 43 mmol/mol ≤ HbA1c ≤ 47 mmol/mol, vs

2. Impaired fasting glucose (IFG): Fasting plasma glucose (FPG): 6.1 mmol/l ≤ FPG ≤ 6.9 mmol/l and HbA1c < 48 mmol/mol, vs

3. Impaired glucose tolerance (IGT): two-hour plasma glucose after 75-g oral glucose tolerance test >7.8 mmol/l with a FPG < 7.0 mmol/l and HbA1c < 48 mmol/mol

• IGT < 11 mmol/l vs IGT >11 mmol/l

• Liraglutide treatment (1.2 mg vs 1.8 mg liraglutide)

• Weight

• Add-on psychotropic drugs/classes (antidepressants, anxiolytics etc. vs no add-on)

• Antihypertensive treatment vs no antihypertensive treatment

• Lipid lowering treatment vs no lipid lowering treatment

• Changes in antipsychotic medication (> 20 % change in dose vs < 20 % change in dose vs no changes in dose for clozapine or olanzapine, respectively)

• Inhalation steroid vs no inhalation steroid

• Body composition

• Insulin resistance

• Beta-cell function

• Incretin hormones

• Psychopathologic rating scales

• Alcohol consumption

• Length of disease

• Diagnosis (schizophrenia vs schizotypal disorder vs paranoid psychosis)

• Side effects

• Serious adverse events

Reference List

1. Foghsgaard S, Vedtofte L, Mathiesen ER et al. The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. BMJ Open 2013;3(10):e003834.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 103
• Est. completion date: March 2017
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Informed oral and written consent

• Diagnosed with schizophrenia, schizotypal disorder or paranoid psychosis according to the criteria of ICD10 (International Classification of Diseases, World Health Organization) or the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, the American Psychiatric Association)

• and on stable antipsychotic treatment with either clozapine or olanzapine for at least 6 months (without dose change for at least 30 days)

• Stable co-medications for at least 30 days.

• Age =18 years and =65 years

• Stable weight (defined as less than 5% change in weight over the last 3 month before inclusion)

• BMI =27 kg/m2

• Dysglycaemia (IFG, i.e. fasting plasma glucose level from 6.1 mmol/L to 6.9 mmol/L or IGT, i.e. two-hour glucose levels > 7.8 mmol/L on the 75-g oral glucose tolerance test with a fasting plasma glucose of less than 7.0 mmol/L and HbA1c < 48 mmol/mol or HbA1c: 43 mmol/mol = HbA1c = 47 mmol/mol)

Exclusion Criteria:

• Compulsory treatment

• Females of child bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures

• Subjects treated with corticosteroids or other hormone therapy (except estrogens)

• Any active substance abuse or dependence for the past 6 months (except for nicotine)

• Impaired hepatic function (liver transaminases >2 times upper normal limit)

• Impaired renal function (se-creatinine >150 µM and/or macroalbuminuria)

• Impaired pancreatic function (acute or chronic pancreatitis and/or amylase >2 times upper normal limit)

• Cardiac problems defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris and/or myocardial infarction within the last 12 months

• Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic blood pressure >100 mmHg)

• Any condition that the investigator feels would interfere with trial participation

• Receiving any investigational drug within the last 3 months

• Use of weight-lowering pharmacotherapy within the preceding 3 month

• Type 1 or 2 diabetes with HbA1c > 6.5%

Also a group of healthy controls (n=10) will have the baseline examinations done. The healthy controls will be matched to our participants in regards to gender, BMI and age. The same inclusion and exclusion criteria will apply for these controls, except these participants are not allowed to have known psychiatric illness, receive anti-psychotic medications, or have a family history of type 2 diabetes (2 generations).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glucose Intolerance
• Impaired Glucose Tolerance Associated With Drugs

Intervention

Drug:
• Liraglutide
Once a day 1,8 mg subcutaneous injection for 16 weeks
• Liraglutide Placebo
Once a day 1,8 mg subcutaneous injection for 16 weeks

Locations

Country	Name	City	State
Denmark	Psychiatric Centre Rigshospitalet	Copenhagen	København Ø

Sponsors (3)

Lead Sponsor	Collaborator
Psychiatric Centre Rigshospitalet	University Hospital, Gentofte, Copenhagen, University of Cambridge

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Alcohol use	AUDIT (Alcohol Use Disorder Identification Test)	Every 4 weeks from baseline - 16 weeks	No
Other	Changes i dietary and exercise records		Every 4 weeks from baseline - 16 weeks	No
Other	Proteomic fingerprinting	We wish to identify baseline imbalances among our participants with proteomic fingerprinting. Furthermore, we will test the dysglycemic and metabolic disturbances in patients treated for 16 weeks with liraglutide or placebo. We wish to investigate, whether treatment with liraglutide possible could rebalance some of the metabolic, immune and hormonal disturbances, we expect to find at baseline.	Every 4 weeks from baseline - 16 weeks	No
Other	Long term follow-up 52 weeks after end of participation	The follow-up 52 weeks after end of participation will include: • Medical history: Changes in antipsychotic medication Changes in other medications Changes in diet and exercise habits Changes in smoking Diagnosed with diabetes or other diseases; Blood sampling; Blood pressure; Weight; Height; Waist circumference; Alcohol Use Disorder Identification Test (AUDIT); Schizophrenia Quality of Life Scale (SQLS); Clinical Global Impression-Severity and Improvement (CGI-S+I); Global Assessment of Function (GAF)	52 weeks after 16 weeks of liraglutide/placebo-treatment	No
Other	Baseline comparisons with healthy controls (non-psychiatric, non-diabetic)	In order to identify risk factors for diabetes development in individuals on antipsychotic medications, the baseline examinations will be performed on a group of healthy controls without psychiatric illnes or pre-diabetes (n=10). The healthy controls will be matched to our participants in regards to gender, age and BMI.	Baseline examination	No
Primary	Glucose tolerance	Change in Glucose tolerance (measured by area under the curve (AUC) for plasma glucose (PG) excursion following a 4-hour 75 g Oral Glucose Tolerance Test (OGTT))	Baseline - 16 weeks	No
Secondary	Dysglycaemia	Change in dysglycaemia (Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT), combined IFG/IGT or diabetes)	Baseline - 16 weeks	No
Secondary	Body weight		Every 4 weeks from baseline - 16 weeks	No
Secondary	Secretion of incretin hormons, insulin sensitivity and beta cell function	Evaluated by Homeostatic Model of Assessment (HOMA)	Baseline - 16 weeks	No
Secondary	Body composition	Dual energy x-ray absorptiometry (DEXA)-scan	Baseline - 16 weeks	No
Secondary	Lipid profile and liver function	Blood sample	Every 4 weeks from baseline - 16 weeks	No
Secondary	Psychopathology	Schizophrenia Quality of Life Scale (SQLS), Clinical Global Impression-Severity (CGI-S), Clinical Global Impression-Improvement (CGI-I), Global Assessment of Function (GAF)	Baseline - 16 weeks	No
Secondary	Waist circumference		Every 4 weeks from baseline - 16 weeks	No
Secondary	Blood pressure		Every 4 weeks from baseline - 16 weeks	No

External Links

•   Web page about the study for patients and caregivers